# KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

> **NCT05149326** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 408 (estimated)

## Conditions studied

- Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** KN046
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05149326
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-20
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05149326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05149326, "KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05149326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*